When I joined Longeveron as CEO, I was intrigued by the potential of our lead investigational product Lomecel-B™ in multiple disease states with clear unmet medical needs, and by the scientific foundation laid for
Divestments in 2023 are important milestones of the Company's execution against its Portfolio Optimization which are part of the set strategic aspirationsDelivers on commitment to improve leverage ratio by allocating